Subscribe to our Newsletters !!
Cell therapy is a medical breakthrough in addressi
Chromium, a transition metal with profound pharmac
Few names in the medical history have had a profou
We are pleased to announce that we have recently e
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and her
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of Mi
The World Health Organization (WHO) is proceeding with its clinical preliminary of hydroxychloroquine, after British researchers ended an enormous preliminary that had been investigating utilization of the medication to treat patients with COVID-19 when beginning outcomes indicated no proof of advantage.
“There are two unmistakable preliminaries with their own conventions, their own oversight advisory groups. Along these lines we will proceed for the time being,” Soumya Swaminathan, the WHO’s main researcher, told an online news instructions when gotten some information about the British preliminary stop.
“Our board will consider the information that becomes available…look at the information inside our preliminary yet in addition consider proof that is coming out of other randomized preliminaries, and we will keep on refreshing you on the advancement of the Solidarity Trial,” she said.
